What medication should be prescribed for a 31-year-old healthy woman with herpes labialis (cold sore) on the lip?

Oral Antiviral Therapy for Herpes Labialis

For a 31-year-old healthy woman with a cold sore on the lip, prescribe either valacyclovir 2 grams twice daily for 1 day OR famciclovir 1500 mg as a single dose. These short-course oral antiviral regimens are FDA-approved and significantly more effective than topical treatments 1.

Why Oral Antivirals Over Topical Agents

Oral systemic antivirals are superior to topical formulations because they:

• Impact the host immune response and inflammatory cascade, not just surface viral replication 1
• Reduce episode duration by approximately 1 day compared to placebo 1
• Offer greater convenience with single-day dosing versus 5-6 times daily topical application 1
• Cannot prevent lesion development with topical application since they don't reach the site of viral reactivation in sensory ganglia 1

Systemic agents have proven highly efficacious in placebo-controlled trials 1, while topical antivirals provide only "small clinical benefit" 1.

Specific Dosing Regimens

First-Line Options (FDA-Approved):

Valacyclovir:

• 2 grams twice daily for 1 day (12 hours apart)
• Significantly reduced median episode duration to 4.0-5.0 days versus 5.0 days with placebo (p <0.001) 1
• Better oral bioavailability than acyclovir 2

Famciclovir:

• 1500 mg as a single dose
• Reduced time to healing of primary lesions (6.2 vs 6.6 days) and time to return to normal skin (2.9 vs 4.5 days, p <0.001) 1
• Alternative: 750 mg twice daily for 1 day 1

Alternative Option:

Acyclovir:

• 400 mg five times daily for 5 days (less convenient)
• 800 mg twice daily for 3-7 days 1
• Requires more frequent dosing but is approved for children (unlike valacyclovir/famciclovir) 2

Critical Timing Consideration

Treatment must be initiated within the first 24-48 hours of symptom onset—ideally during the prodromal stage (tingling, burning, itching)—to achieve optimal therapeutic benefit 1, 2. Peak viral titers occur in the first 24 hours when lesions are vesicular, and natural healing begins within this window 1. Delayed treatment significantly reduces efficacy.

Safety Profile

All three oral antivirals are well-tolerated with minimal adverse events 1:

• Headache is the most common side effect (mild-to-moderate, <10% of patients)
• Nausea occurs in <4% of patients
• No serious adverse events reported in clinical trials 1

When to Consider Chronic Suppressive Therapy

For patients with six or more episodes per year or severe/frequent recurrences 2:

• Valacyclovir 500 mg once daily
• Acyclovir 400 mg twice daily
• Famciclovir (dosing varies)

Suppressive therapy significantly reduces recurrence frequency: 53% fewer clinical recurrences with acyclovir versus placebo (p=0.009), and 60% of patients remained recurrence-free with valacyclovir versus 38% with placebo 1.

Common Pitfalls to Avoid

1. Don't prescribe topical antivirals alone for episodic treatment—they require 5-6 applications daily and provide minimal benefit 1
2. Don't delay treatment waiting for full lesion development—efficacy drops significantly after 48 hours 2
3. Don't use topical antivirals for prophylaxis—they cannot reach the site of viral reactivation 1
4. Educate patients to keep medication on hand and self-initiate at first prodromal symptoms 1

Additional Preventive Measures

For patients with frequent UV-triggered recurrences, recommend sunscreen (SPF 15 or above) for prevention 3, 4. One study showed significantly reduced HL attacks with SPF 30 lip protection during summer 4.